In a report published Monday, Piper Jaffray & Co. reiterated its Neutral rating and $10.00 price target on ISIS Pharmaceuticals (NASDAQ: ISIS ). Piper Jaffray noted, “This morning, ISIS signed a new antisense collaboration with Biogen Idec (BIIB) for 3 undisclosed neurological and neuromuscular targets. Although the deal brings in